Cargando…

Immune Phenotypic Characterization of a TRAIL-Knockout Mouse

SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoyanova, Ani K., Sattler, Arne, Hahn, Elisabeth M., Hering, Nina A., Arndt, Marco, Lauscher, Johannes Christian, Speichinger-Hillenberg, Fiona, Kotsch, Katja, Berg, Ann-Kathrin, Beyer, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000729/
https://www.ncbi.nlm.nih.gov/pubmed/36900266
http://dx.doi.org/10.3390/cancers15051475
_version_ 1784903951440674816
author Stoyanova, Ani K.
Sattler, Arne
Hahn, Elisabeth M.
Hering, Nina A.
Arndt, Marco
Lauscher, Johannes Christian
Speichinger-Hillenberg, Fiona
Kotsch, Katja
Berg, Ann-Kathrin
Beyer, Katharina
author_facet Stoyanova, Ani K.
Sattler, Arne
Hahn, Elisabeth M.
Hering, Nina A.
Arndt, Marco
Lauscher, Johannes Christian
Speichinger-Hillenberg, Fiona
Kotsch, Katja
Berg, Ann-Kathrin
Beyer, Katharina
author_sort Stoyanova, Ani K.
collection PubMed
description SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse model and should serve as a tool to study the functional relevance of TRAIL in proof-of-concept studies. ABSTRACT: The TNF-superfamily member TRAIL is known to mediate selective apoptosis in tumor cells suggesting this protein as a potential antitumor drug target. However, initial successful pr-clinical results could not be translated into the clinic. Reasons for the ineffectiveness of TRAIL-targeting in tumor therapies could include acquired TRAIL resistance. A tumor cell acquires TRAIL resistance, for example, by upregulation of antiapoptotic proteins. In addition, TRAIL can also influence the immune system and thus, tumor growth. We were able to show in our previous work that TRAIL(−/−) mice show improved survival in a mouse model of pancreatic carcinoma. Therefore, in this study we aimed to immunologically characterize the TRAIL(−/−) mice. We observed no significant differences in the distribution of CD3(+), CD4(+), CD8(+) T-cells, Tregs, and central memory CD4(+) and CD8(+) cells. However, we provide evidence for relevant differences in the distribution of effector memory T-cells and CD8(+)CD122(+) cells but also in dendritic cells. Our findings suggest that T-lymphocytes of TRAIL(−/−) mice proliferate at a lower rate, and that the administration of recombinant TRAIL significantly increases their proliferation, while regulatory T-cells (Tregs) from TRAIL(−/−) mice are less suppressive. Regarding the dendritic cells, we found more type-2 conventional dendritic cells (DC2s) in the TRAIL(−/−) mice. For the first time (to the best of our knowledge), we provide a comprehensive characterization of the immunological landscape of TRAIL-deficient mice. This will establish an experimental basis for future investigations of TRAIL-mediated immunology.
format Online
Article
Text
id pubmed-10000729
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100007292023-03-11 Immune Phenotypic Characterization of a TRAIL-Knockout Mouse Stoyanova, Ani K. Sattler, Arne Hahn, Elisabeth M. Hering, Nina A. Arndt, Marco Lauscher, Johannes Christian Speichinger-Hillenberg, Fiona Kotsch, Katja Berg, Ann-Kathrin Beyer, Katharina Cancers (Basel) Article SIMPLE SUMMARY: The role of the TNF-superfamily member TRAIL (TNF-related apoptosis inducing ligand) for potential interactions with the immunological tumor network is not completely understood. This article provides a comprehensive immune phenotype profile of a TRAIL-knockout (TRAIL(−/−)) mouse model and should serve as a tool to study the functional relevance of TRAIL in proof-of-concept studies. ABSTRACT: The TNF-superfamily member TRAIL is known to mediate selective apoptosis in tumor cells suggesting this protein as a potential antitumor drug target. However, initial successful pr-clinical results could not be translated into the clinic. Reasons for the ineffectiveness of TRAIL-targeting in tumor therapies could include acquired TRAIL resistance. A tumor cell acquires TRAIL resistance, for example, by upregulation of antiapoptotic proteins. In addition, TRAIL can also influence the immune system and thus, tumor growth. We were able to show in our previous work that TRAIL(−/−) mice show improved survival in a mouse model of pancreatic carcinoma. Therefore, in this study we aimed to immunologically characterize the TRAIL(−/−) mice. We observed no significant differences in the distribution of CD3(+), CD4(+), CD8(+) T-cells, Tregs, and central memory CD4(+) and CD8(+) cells. However, we provide evidence for relevant differences in the distribution of effector memory T-cells and CD8(+)CD122(+) cells but also in dendritic cells. Our findings suggest that T-lymphocytes of TRAIL(−/−) mice proliferate at a lower rate, and that the administration of recombinant TRAIL significantly increases their proliferation, while regulatory T-cells (Tregs) from TRAIL(−/−) mice are less suppressive. Regarding the dendritic cells, we found more type-2 conventional dendritic cells (DC2s) in the TRAIL(−/−) mice. For the first time (to the best of our knowledge), we provide a comprehensive characterization of the immunological landscape of TRAIL-deficient mice. This will establish an experimental basis for future investigations of TRAIL-mediated immunology. MDPI 2023-02-25 /pmc/articles/PMC10000729/ /pubmed/36900266 http://dx.doi.org/10.3390/cancers15051475 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stoyanova, Ani K.
Sattler, Arne
Hahn, Elisabeth M.
Hering, Nina A.
Arndt, Marco
Lauscher, Johannes Christian
Speichinger-Hillenberg, Fiona
Kotsch, Katja
Berg, Ann-Kathrin
Beyer, Katharina
Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title_full Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title_fullStr Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title_full_unstemmed Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title_short Immune Phenotypic Characterization of a TRAIL-Knockout Mouse
title_sort immune phenotypic characterization of a trail-knockout mouse
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000729/
https://www.ncbi.nlm.nih.gov/pubmed/36900266
http://dx.doi.org/10.3390/cancers15051475
work_keys_str_mv AT stoyanovaanik immunephenotypiccharacterizationofatrailknockoutmouse
AT sattlerarne immunephenotypiccharacterizationofatrailknockoutmouse
AT hahnelisabethm immunephenotypiccharacterizationofatrailknockoutmouse
AT heringninaa immunephenotypiccharacterizationofatrailknockoutmouse
AT arndtmarco immunephenotypiccharacterizationofatrailknockoutmouse
AT lauscherjohanneschristian immunephenotypiccharacterizationofatrailknockoutmouse
AT speichingerhillenbergfiona immunephenotypiccharacterizationofatrailknockoutmouse
AT kotschkatja immunephenotypiccharacterizationofatrailknockoutmouse
AT bergannkathrin immunephenotypiccharacterizationofatrailknockoutmouse
AT beyerkatharina immunephenotypiccharacterizationofatrailknockoutmouse